Transactivation of cellular genes involved in nucleotide metabolism by the regulatory IE1 protein of murine cytomegalovirus is not critical for viral replicative fitness in quiescent cells and host tissues

Journal of Virology

Volumn 82, Issue 20, 2008, Pages 9900-9916

  Wilhelmi, Vanessa ^a   Simon, Christian O ^a   Podlech, Jürgen ^a   Böhm, Verena ^a   Däubner, Torsten ^a   Emde, Simone ^a   Strand, Dennis ^b   Renzaho, Angélique ^a   Lemmermann, Niels A W ^a   Seckert, Christof K ^a   Reddehase, Matthias J ^a   Grzimek, Natascha K A ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN 1; NUCLEOSIDE TRIPHOSPHATASE; REGULATOR PROTEIN; RIBONUCLEOTIDE REDUCTASE; THYMIDINE PHOSPHATE; UNCLASSIFIED DRUG; VIRUS PROTEIN; IE1 PROTEIN, CYTOMEGALOVIRUS; NUCLEOTIDE; PEPTIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CYTOMEGALOVIRUS; ENZYME ACTIVATION; FEMALE; GENE ACTIVATION; GENETIC TRANSFECTION; HOST; IN VIVO STUDY; MICROBIAL ATTENUATION; MOUSE; MURINE CYTOMEGALOVIRUS; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; STRAIN DIFFERENCE; TISSUE; VIROGENESIS; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BETAHERPESVIRINAE; CELL CULTURE; CELL STRAIN 3T3; CYTOLOGY; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; POINT MUTATION; PROMOTER REGION; SEQUENCE ALIGNMENT; TRANSACTIVATION; VIROLOGY;

MURID HERPESVIRUS 1; MURINAE;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CELLS, CULTURED; FIBROBLASTS; GENE EXPRESSION REGULATION; IMMEDIATE-EARLY PROTEINS; LIVER; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MUROMEGALOVIRUS; NIH 3T3 CELLS; NUCLEOTIDES; PEPTIDES; POINT MUTATION; PROMOTER REGIONS (GENETICS); SEQUENCE ALIGNMENT; TRANS-ACTIVATION (GENETICS); VIRUS REPLICATION;

EID: 53749098357     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00928-08     Document Type: Article

References (94)

1. Adachi, N., and M. R. Lieber. 2002. Bidirectional gene organization: a common architectural feature of the human genome. Cell 109:807-809.
2. Angulo, A., P. Ghazal, and M. Messerle. 2000. The major immediate-early gene ie3 of mouse cytomegalovirus is essential for viral growth. J. Virol. 74:11129-11136.
3. Applied Biosystems. 2001. User bulletin no. 2: ABI Prism 7700 Sequence Detection System (manual no. 10/2001). Applied Biosystems, Foster City, CA.
4. Ash, J., W.-C. Liao, Y. Ke, and L. F. Johnson. 1995. Regulation of mouse thymidylate synthase gene expression in growth-stimulated cells: upstream S phase control elements are indistinguishable from essential promoter elements. Nucleic Acids Res. 23:4649-4656.
5. Bain, M., M. Reeves, and J. Sinclair. 2006. Regulation of human cytomegalovirus gene expression by chromatin remodeling, p. 167-183. In M. J. Reddehase (ed.), Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Wymondham, Norfolk, United Kingdom.
6. Böhm, V., J. Podlech, D. Thomas, P. Deegen, M. F. Pahl-Seibert, N. A. Lemmermann, N. K. Grzimek, S. A. Oehrlein-Karpi, M. J. Reddehase, and R. Holtappels. 2008. Epitope-specific in vivo protection against cytomegalovirus disease by CD8 T cells in the murine model of preemptive immunotherapy. Med. Microbiol. Immunol. 197:135-144.
7. Böhme, K. W., and T. Compton. 2006. Virus entry and activation of innate immunity, p. 111-130. In M. J. Reddehase (ed.), Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Wymondham, Norfolk, United Kingdom.
8. Borst, E. M., G. Hahn, U. H. Koszinowski, and M. Messerle. 1999. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol. 73:8320-8329.
9. Borst, E. M., G. Posfai, F. Pogoda, and M. Messerle. 2004. Mutagenesis of herpesvirus BACs by allele replacement. Methods Mol. Biol. 256:269-279.
10. Borysiewicz, L. K., J. K. Hickling, S. Graham, J. Sinclair, M. P. Cranage, G. L. Smith, and J. G. Sissons. 1988. Human cytomegalovirus- specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia virus. J. Exp. Med. 168:919-931.
11. Bühler, B., G. M. Keil, F. Weiland, and U. H. Koszinowski. 1990. Characterization of the murine cytomegalovirus early transcription unit e1 that is induced by immediate-early proteins. J. Virol. 64:1907-1919.
12. Bunde, T., A. Kirchner, B. Hoffmeister, D. Habedank, R. Hetzer, G. Cherepnev, S. Prösch, P. Reinke, H. D. Volk, H. Lehmkuhl, and F. Kern. 2005. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J. Exp. Med. 201:1031-1036.
13. Busche, A., A. Angulo, P. Kay-Jackson, P. Ghazal, and M. Messerle. 2008. Phenotypes of major immediate-early gene mutants of mouse cytomegalovirus. Med. Microbiol. Immunol. 197:233-240.
14. Cardin, R. D., G. B. Abenes, C. A. Stoddard, and E. S. Mocarski. 1995. Murine cytomegalovirus IE2, an activator of gene expression, is dispensable for growth and latency in mice. Virology 209:236-241.
15. Chabes, A., and L. Thelander. 2000. Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks. J. Biol. Chem. 275:17747-17753.
16. Chatellard, P., R. Pankiewicz, E. Meier, L. Durrer, C. Sauvage, and M. O. Imhof. 2007. The IE2 promoter/enhancer region from mouse CMV provides high levels of therapeutic protein expression in mammalian cells. Biotechnol. Bioeng. 96:106-117.
17. Cicin-Sain, L., Z. Ruzsics, J. Podlech, I. Bubic, C. Menard, S. Jonjic, M. J. Reddehase, and U. H. Koszinowski. 2008. Dominant-negative FADD rescues the in vivo fitness of a cytomegalovirus lacking an antiapoptotic viral gene. J. Virol. 82:2056-2064.
18. Ciocco-Schmitt, G. M., Z. Karabekian, E. W. Godfrey, R. M. Stenberg, A. E. Campbell, and J. A. Kerry. 2002. Identification and characterization of novel murine cytomegalovirus M112-113 (e1) gene products. Virology 294:199-208.
19. Cumming, R. C., N. L. Andon, P. A. Haynes, M. Park, W. H. Fischer, and D. Schubert. 2004. Protein disulfide bond formation in the cytoplasm during oxidative stress. J. Biol. Chem. 279:21749-21758.
20. Dorsch-Häsler, K., G. M. Keil, F. Weber, M. Jasin, W. Schaffner, and U. H. Koszinowski. 1985. A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus. Proc. Natl. Acad. Sci. USA 82:8325-8329.
21. Ebeling, A., G. M. Keil, E. Knust, and U. H. Koszinowski. 1983. Molecular cloning and physical mapping of murine cytomegalovirus DNA. J. Virol. 47:421-433.
22. Erlach, K. C., V. Böhm, M. Knabe, P. Deegen, M. J. Reddehase, and J. Podlech. 2008. Activation of hepatic natural killer cells and control of liver-adapted lymphoma in the murine model of cytomegalovirus infection. Med. Microbiol. Immunol. 197:167-178.
23. Gawn, J. M., and R. F. Greaves. 2002. Absence of IE1 p72 protein function during low-multiplicity infection by human cytomegalovirus results in a broad block to viral delayed-early gene expression. J. Virol. 76:4441-4455.
24. Gerdes, J., L. Li, C. Schlueter, M. Duchrow, C. Wohlenberg, C. Gerlach, I. Stahmer, S. Kloth, E. Brandt, and H. D. Flad. 1991. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am. J. Pathol. 138:867-873.
25. Ghazal, P., M. Messerle, K. Osborn, and A. Angulo. 2003. An essential role of the enhancer for murine cytomegalovirus in vivo growth and pathogenesis. J. Virol. 77:3217-3228.
26. Ghazal, P., A. E. Visser, M. Gustems, R. Garcia, E. M. Borst, K. Sullivan, M. Messerle, and A. Angulo. 2005. Elimination of ie1 significantly attenuates murine cytomegalovirus virulence but does not alter replicative capacity in cell culture. J. Virol. 79:7182-7194.
27. Gibson, L., G. Piccinini, D. Lilleri, M. G. Revello, Z. Wang, S. Markel, D. J. Diamond, and K. Luzuriaga. 2004. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection. J. Immunol. 172:2256-2264.
28. Greaves, R. F., and E. S. Mocarski. 1998. Defective growth correlates with reduced accumulation of a viral DNA replication protein after low-multiplicity infection by a human cytomegalovirus ie1 mutant. J. Virol. 72:366-379.
29. Gribaudo, G., L. Riera, D. Lembo, M. De Andrea, M. Gariglio, T. L. Rudge, L. F. Johnson, and S. Landolfo. 2000. Murine cytomegalovirus stimulates cellular thymidylate synthase gene expression in quiescent cells and requires the enzyme for replication. J. Virol. 74:4979-4987.
30. Grzimek, N. K. A., D. Dreis, S. Schmalz, and M. J. Reddehase. 2001. Random, asynchronous, and asymmetric transcriptional activity of enhancer-flanking major immediate-early genes ie1/3 and ie2 during murine cytomegalovirus latency in the lungs. J. Virol. 75:2692-2705.
31. Grzimek, N. K. A., J. Podlech, H.-P. Steffens, R. Holtappels, S. Schmalz, and M. J. Reddehase. 1999. In vivo replication of recombinant murine cytomegalovirus driven by the paralogous major immediate-early promoter-enhancer of human cytomegalovirus. J. Virol. 73:5043-5055.
32. Harlow, E., and D. Lane. 1988. Antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
33. Holtappels, R., V. Böhm, J. Podlech, and M. J. Reddehase. 2008. CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model. Med. Microbiol. Immunol. 197:125-134.
34. Holtappels, R., D. Gillert-Marien, D. Thomas, J. Podlech, P. Deegen, S. Herter, S. A. Oehrlein-Karpi, D. Strand, M. Wagner, and M. J. Reddehase. 2006. Cytomegalovirus encodes a positive regulator of antigen presentation. J. Virol. 80:7613-7624.
35. Holtappels, R., M. W. Munks, J. Podlech, and M. J. Reddehase. 2006. CD8 T-cell-based immunotherapy of cytomegalovirus disease in the mouse model of the immunocompromised bone marrow transplantation recipient, p. 383-418. In M. J. Reddehase (ed.), Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Wymondham, Norfolk, United Kingdom.
36. lo memory-effector cell pool during latent murine cytomegalovirus infection of the lungs. J. Virol. 74:11495-11503.
37. Holtappels, R., C. O. Simon, M. W. Munks, D. Thomas, P. Deegen, B. Kühnapfel, T. Däubner, S. F. Emde, J. Podlech, N. K. Grzimek, S. A. Oehrlein-Karpi, A. B. Hill, and M. J. Reddehase. 2008. Subdominant CD8 T-cell epitopes account for protection against cytomegalovirus independent of immunodomination. J. Virol. 82:5781-5796.
38. d haplotype. J. Virol. 76:151-164.
39. + T cells over time. J. Immunol. 170:2022-2029. (Erratum, 170:3895.)
40. Keil, G. M., A. Ebeling-Keil, and U. H. Koszinowski. 1984. Temporal regulation of murine cytomegalovirus transcription and mapping of viral RNA synthesized at immediate early times after infection. J. Virol. 50:784-795.
41. Keil, G. M., A. Ebeling-Keil, and U. H. Koszinowski. 1987. Immediate-early genes of murine cytomegalovirus: location, transcripts, and translation products. J. Virol. 61:526-533.
42. Keil, G. M., A. Ebeling-Keil, and U. H. Koszinowski. 1987. Sequence and structural organization of murine cytomegalovirus immediate-early gene 1. J. Virol. 61:1901-1908.
43. Keil, G. M., M. R. Fibi, and U. H. Koszinowski. 1985. Characterization of the major immediate-early polypeptides encoded by murine cytomegalovirus. J. Virol. 54:422-428.
44. +-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J. Virol. 73:8179-8184.
45. Knuehl, C., P. Spee, T. Ruppert, U. Kuckelkorn, P. Henklein, J. Neefjes, and P. M. Kloetzel. 2001. The murine cytomegalovirus pp89 immunodominant H-2Ld epitope is generated and translocated into the endoplasmic reticulum as an 11-mer precursor peptide. J. Immunol. 167:1515-1521.
46. Kurz, S. K., M. Rapp, H.-P. Steffens, N. K. A. Grzimek, S. Schmalz, and M. J. Reddehase. 1999. Focal transcriptional activity of murine cytomegalovirus during latency in the lungs. J. Virol. 73:482-494.
47. Kurz, S. K., H.-P. Steffens, A. Mayer, J. R. Harris, and M. J. Reddehase. 1997. Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs. J. Virol. 71:2980-2987.
48. Lembo, D., M. Donalisio, A. Hofer, M. Cornaglia, W. Brune, U. H. Koszinowski, L. Thelander, and S. Landolfo. 2004. The ribonucleotide reductase R1 homolog of murine cytomegalovirus is not a functional enzyme subunit but is required for pathogenesis. J. Virol. 78:4278-4288.
49. Lembo, D., G. Gribaudo, A. Hofer, L. Riera, M. Cornaglia, A. Mondo, A. Angeretti, M. Gariglio, L. Thelander, and S. Landolfo. 2000. Expression of an altered ribonucleotide reductase activity associated with the replication of murine cytomegalovirus in quiescent fibroblasts. J. Virol. 74:11557- 11565.
50. Liao, W. C., J. Ash, and L. F. Johnson. 1994. Bidirectional promoter of the mouse thymidylate synthase gene. Nucleic Acids Res. 22:4044-4049.
51. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25:402-408.
52. Maul, G. G. 2008. Initiation of cytomegalovirus infection at ND10. Curr. Top. Microbiol. Immunol. 325:117-132.
53. Maul, G. G., and D. Negorev. 2008. Differences between mouse and human cytomegalovirus interactions with their respective hosts at immediate early times of the replication cycle. Med. Microbiol. Immunol. 197:241-249.
54. Meier, J. L., and M. F. Stinski. 2006. Major immediate-early enhancer and its gene products, p. 151-166. In M. J. Reddehase (ed.), Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Wymondham, Norfolk, United Kingdom.
55. Messerle, M., B. Bühler, G. M. Keil, and U. H. Koszinowski. 1992. Structural organization, expression, and functional characterization of the murine cytomegalovirus immediate-early gene 3. J. Virol. 66:27-36.
56. Messerle, M., I. Crnkovic, W. Hammerschmidt, H. Ziegler, and U. H. Koszinowski. 1997. Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc. Natl. Acad. Sci. USA 94:14759-14763.
57. Messerle, M., G. M. Keil, and U. H. Koszinowski. 1991. Structure and expression of murine cytomegalovirus immediate-early gene 2. J. Virol. 65:1638-1643.
58. Nielsen, M., C. Lundegaard, O. Lund, and C. Keçsmir. 2005. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 57:33-41.
59. O'Connor, M., M. Peifer, and W. Bender. 1989. Construction of large DNA segments in Escherichia coli. Science 244:1307-1312.
60. Overbergh, L., D. Valckx, M. Waer, and C. Mathieu. 1999. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 11:305-312.
61. Pahl-Seibert, M.-F., M. Juelch, J. Podlech, D. Thomas, P. Deegen, M. J. Reddehase, and R. Holtappels. 2005. Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting. J. Virol. 79:5400-5413.
62. Paulus, C., S. Krauss, and M. Nevels. 2006. A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc. Natl. Acad. Sci. USA 103:3840-3845.
63. Podlech, J., R. Holtappels, N. K. A. Grzimek, and M. J. Reddehase. 2002. Animal models: murine cytomegalovirus, p. 493-525. In S. H. E. Kaufmann and D. Kabelitz (ed.), Methods in microbiology, immunology of infection, 2nd ed., vol. 32. Academic Press, San Diego, CA.
64. Qiagen. 2006. DNeasy blood and tissue handbook (manual no. 07/2006). Qiagen, Hilden, Germany.
65. Qiagen. 2007. RNeasy micro handbook (manual no. 12/2007). Qiagen, Hilden, Germany.
66. Qiagen. 2006. RNeasy mini handbook (manual no. 04/2006). Qiagen, Hilden, Germany.
67. Rawlinson, W. D., H. E. Farrell, and B. G. Barrell. 1996. Analysis of the complete DNA sequence of murine cytomegalovirus. J. Virol. 70:8833-8849.
68. Reddehase, M. J. 2002. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat. Rev. Immunol. 2:831-844.
69. Reddehase, M. J., and U. H. Koszinowski. 1984. Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection. Nature 312:369-371.
70. Reddehase, M. J., and U. H. Koszinowski. 1991. Redistribution of critical major histocompatibility complex and T cell receptor-binding functions of residues in an antigenic sequence after biterminal substitution. Eur. J. Immunol. 21:1697-1701.
71. Reddehase, M. J., W. Mutter, K. Münch, H. J. Bühring, and U. H. Koszinowski. 1987. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J. Virol. 61:3102-3108.
72. Reddehase, M. J., J. B. Rothbard, and U. H. Koszinowski. 1989. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature 337:651-653.
73. Reddehase, M. J., C. O. Simon, C. K. Seckert, N. Lemmermann, and N. K. A. Grzimek. 2008. Murine model of cytomegalovirus latency and reactivation. Curr. Top. Microbiol. Immunol., vol 325:315-332.
74. Sacher, T., J. Podlech, C. A. Mohr, S. Jordan, Z. Ruzsics, M. J. Reddehase, and U. H. Koszinowski. 2008. The major virus-producing cell type during murine cytomegalovirus infection, the hepatocyte, is not the source of virus dissemination in the host. Cell Host Microbe 3:263-272.
75. Sanchez, V., and D. Spector. 2006. Exploitation of host cell cycle regulatory pathways by HCMV, p. 205-230. In M. J. Reddehase (ed.), Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Wymondham, Norfolk, United Kingdom.
76. Seckert, C. K., A. Renzaho, M. J. Reddehase, and N. K. Grzimek. 2008. Hematopoietic stem cell transplantation with latently infected donors does not transmit virus to immunocompromised recipients in the murine model of cytomegalovirus infection. Med. Microbiol. Immunol. 197:251-259.
77. 2+ on enzymatic dispersion of isolated, perfused liver. Exp. Cell Res. 74:450-454.
78. Seglen, P. O. 1973. Preparation of rat liver cells. III. Enzymatic requirements for tissue dispersion. Exp. Cell Res. 82:391-398.
79. Shenk, T. 2006. Human cytomegalovirus genomics, p. 49-62. In M. J. Reddehase (ed.), Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Wymondham, Norfolk, United Kingdom.
80. Simon, C. O., R. Holtappels, H.-M. Tervo, V. Böhm, T. Däubner, S. A. Oehrlein-Karpi, B. Kühnapfel, A. Renzaho, D. Strand, J. Podlech, M. J. Reddehase, and N. K. A. Grzimek. 2006. CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J. Virol. 80:10436-10456.
81. Simon, C. O., B. Kühnapfel, M. J. Reddehase, and N. K. Grzimek. 2007. Murine cytomegalovirus major immediate-early enhancer region operating as a genetic switch in bidirectional gene pair transcription. J. Virol. 81:7805-7810.
82. Simon, C. O., C. K. Seckert, D. Dreis, M. J. Reddehase, and N. K. Grzimek. 2005. Role for tumor necrosis factor alpha in murine cytomegalovirus transcriptional reactivation in latently infected lungs. J. Virol. 79:326-340.
83. Simon, C. O., C. K. Seckert, N. K. A. Grzimek, and M. J. Reddehase. 2006. Murine model of cytomegalovirus latency and reactivation: the silencing/desilencing and immune sensing hypothesis, p. 483-500. In M. J. Reddehase (ed.), Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Wymondham, Norfolk, United Kingdom.
84. Stinski, M. F., and H. Isomura. 2008. Role of the cytomegalovirus major immediate early enhancer in acute infection and reactivation from latency. Med. Microbiol. Immunol. 197:223-231.
85. Stinski, M. F., and D. T. Petrik. 2008. Functional roles of the human cytomegalovirus essential IE86 protein. Curr. Top Microbiol. Immunol. 325:133-152.
86. + T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202:673-685.
87. Tang, Q., L. Li, and G. G. Maul. 2005. Mouse cytomegalovirus early M112/113 proteins control the repressive effect of IE3 on the major immediateearly promoter. J. Virol. 79:257-263.
88. Tang, Q., and G. G. Maul. 2003. Mouse cytomegalovirus immediate-early protein 1 binds with host cell repressors to relieve suppressive effects on viral transcription and replication during lytic infection. J. Virol. 77:1357-1367.
89. Tang, Q., and G. G. Maul. 2006. Immediate-early interactions and epigenetic defense mechanisms, p. 131-149. In M. J. Reddehase (ed.), Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Wymondham, Norfolk, United Kingdom.
90. Tenzer, S., B. Peters, S. Bulik, O. Schoor, C. Lemmel, M. M. Schatz, P. M. Kloetzel, H. G. Rammensee, H. Schild, and H. G. Holzhütter. 2005. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol. Life Sci. 62:1025-1037.
91. Trinklein, N. D., S. F. Aldred, S. J. Hartman, D. I. Schroeder, R. P. Otillar, and R. M. Myers. 2004. An abundance of bidirectional promoters in the human genome. Genome Res. 14:62-66.
92. Voigt, S., G. R. Sandford, G. S. Hayward, and W. H. Burns. 2005. The English strain of rat cytomegalovirus (CMV) contains a novel captured CD200 (vOX2) gene and a spliced CC chemokine upstream from the major immediate-early region: further evidence for a separate evolutionary lineage from that of rat CMV Maastricht. J. Gen. Virol. 86:263-274.
93. Wagner, M., S. Jonjic, U. H. Koszinowski, and M. Messerle. 1999. Systematic excision of vector sequences from the BAC-cloned herpesvirus genome during virus reconstitution. J. Virol. 73:7056-7060.
94. Xu, Y., S. A. Cei, A. Rodriguez Huete, K. S. Celletti, and G. S. Pari. 2004. Human cytomegalovirus DNA replication requires transcriptional activation via an IE2- and UL84-responsive bidirectional promoter element within oriLyt. J. Virol. 78:11664-11677.